The data, according to Medtronic, demonstrates that using the system allows people with diabetes to meet or exceed internationally recommended targets regardless of location. The medtech giant says a barrier to automated insulin delivery (AID) adoption and reimbursement in developing and middle-income countries has been a lack of data supporting its performance and cost-effectiveness in those regions. This comes as a result of large disparities in ethnic, cultural and regional representation in clinical and real-world studies.
Medtronic said its successful results support calls to provide AID systems within underserved populations. Data came from more than 67,000 MiniMed 780G users in Europe, the Middle East, Africa, Latin America, Oceania and Asia. The company presented its data at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting in Hamburg, Germany.
Data demonstrated that average glycemic control exceeded internationally recommended targets. The American Diabetes Association recommends 70% time in range between 70-180 mg/dL. Using MiniMed 780G further improves glycemic outcomes and narrows the differences across regions, the company said. This suggests that the system nearly equalizes performance across disparate regions of the world.
“As AID systems have taken a foothold among western countries, we’ve seen the growing success of outcomes from algorithms, such as SmartGuard technology, to reduce the burden of living with diabetes,” said Federico Gavioli, SVP of Medtronic Diabetes, EMEA & Americas. “That said, there continues to be gaps in access among under-served populations given false perceptions about the impacts of cultural differences to the ultimate success of patients. With the growing body of data, we’re proving that the ideal user of the MiniMed 780G system is anyone who is living with diabetes, regardless of region, religion, or cultural differences.”
More about the Medtronic MiniMed 780G
MiniMed 780G received FDA approval in April of this year. It cleared another major hurdle with Medicare coverage announced in July.
The system features glucose target settings as low as 100 mg/dL — the lowest in any automated insulin pump on the market. It closely mirrors the average glucose of someone not living with diabetes, according to the company
This setting enables the pump to “treat to target.” It automatically delivers basal insulin adjustments and autocorrections to a set target. Medtronic said it’s the only pump with an infusion set capable of a wear time of up to seven days. The company launched this infusion set — which doubles the previous wear time — in November 2022. The set also features advanced materials to help reduce insulin preservation loss and maintain insulin flow and stability. This results in a reduced risk of infusion set occlusion.
Combined with Guardian 4, MiniMed 780G offers a user-friendly design. The company says 94% of users report satisfaction with the impact the system has on their quality of life. Users also reported remaining in SmartGuard technology mode 95% of the time.
MiniMed 780G also features SmartGuard technology to eliminate the need for fingersticks. Its Meal Detection Technology provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs. Que Dallara, Medtronic Diabetes EVP and president, told Drug Delivery Business News that this feature is “a big deal.”
Medtronic also presented strong data supporting Meal Detection Technology at the American Diabetes Association Scientific Sessions in June.
Data on Muslims with diabetes who observe Ramadan
For people with type 1 diabetes, fasting during the month of Ramadan can bring a high risk of complications. Those include hypoglycemia, hyperglycemia, dehydration, and diabetic ketoacidosis, particularly during the fasting hours (from Fajr to Maghrib prayer).
Although those with diabetes have an exemption, many choose to fast, Medtronic said. A separate analysis of real-world data showed that people in the Gulf region using MiniMed 780G over Ramadan experienced consistent time in range, time below range and mean sugar glucose before, during and after Ramadan.
The analysis saw no increased risk of hypoglycemia during the Ramadan fasting hours, despite the presumed risk.
Medtronic said Ramadan encompasses substantial lifestyle modifications, like alterations in dietary habits, exercise and sleep patterns. This evidence, the company said, highlights how MiniMed780G performs well across different demographics and cultures while adapting to other scenarios involving lifestyle changes.
Even more impressive performance for ‘time in tight range’
People with diabetes are encouraged to achieve greater than 70% time in range. Time in tight range, once considered an aggressive target for diabetes management, lowers the threshold. This recently introduced metric sits between 70-140 mg/dL.
Medtronic also presented data demonstrating that users of MiniMed 780G, on average, reach a time in tight range of 48.9%. Some even reached up to 56.1% when using recommended settings.
The company said that previous evidence indicated the importance of those recommended settings for achieving a high time in range. It says the data proved that it’s even more crucial to consistently adhere to recommended settings to achieve tight time in range.
“As the clinical and real-world evidence for the MiniMed 780G system continues to build, the system is demonstrating its ability to support individuals achieving even greater outcomes,” Medtronic says.
